0
MorphoSys AG Banner Image

MorphoSys AG has reached its limit for free report views

Work for MorphoSys AG? Upgrade Your Profile and unlock all your annual reports.

MorphoSys AG

  • Ticker MOR
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
MorphoSys AG Logo Image
  • 501-1000 Employees
  • Based in Planegg, Germany
MorphoSys (FSE & NASDAQ: MOR) is a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributedMore to the development of more than 100 product candidates, of which 27 are currently in clinical development. In 2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys' antibody technology to receive regulatory approval. In July 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval of the company's proprietary product Monjuvi(R) (tafasitamab-cxix) in combination with lenalidomide in patients with a certain type of lymphoma. Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has ~500 employees.
MorphoSys AG

Most Recent Annual Report

MorphoSys AG MOST RECENT 2019 Annual Report

Report Locked. MorphoSys AG has reached its limit for free report views.

Older/Archived Annual Reports